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Novelty and Impact 
In this work, we assess for the first time the genetic landscape of  CLLs with IGH 
rearrangements by targeted NGS, characterizing recurrently mutated genes with 
prognostic implications and demonstrating that these entities exhibit an intermed iate 
mutational profile between CLL and non-Hodgkin lymphoma. Moreover, our findings 
showed that the incorporation of NGS and the IGH-probe in the CLL-FISH panel used in 
clinical routine could be extremely useful, especially for elucidating prognosis in ‘normal 
FISH’ cases.  




Chromosome 14q32 rearrangements/translocations involving the immunoglobulin heavy 
chain (IGH) are rarely detected in chronic lymphocytic leukemia (CLL). The prognostic 
significance of the IGH translocation is controversial and its mutational profile remains 
unknown. Here, we present for the first time a comprehensive next-generation sequencing 
(NGS) analysis of 46 CLL patients with IGH rearrangement (IGHR-CLLs) and we 
demonstrate that IGHR-CLLs have a distinct mutational profile with recurrent mutations 
in NOTCH1, IGLL5, POT1, BCL2, FBXW7, ZMYM3, MGA, BRAF and HIST1H1E genes. 
Interestingly, BCL2 and FBXW7 mutations were significantly associated with this 
subgroup and almost half of BCL2, IGLL5 and HISTH1E mutations reported were 
previously identified in non-Hodgkin lymphomas (NHL). Notably, IGH/BCL2 
rearrangements were associated with a lower mutation frequency and carried BCL2 and 
IGLL5 mutations, while the other IGHR-CLLs had mutations in genes related to poor 
prognosis (NOTCH1, SF3B1 and TP53) and shorter time to first treatment (TFT). 
Moreover, IGHR-CLLs patients showed a shorter TFT than  CLL patients carrying 13q-, 
normal FISH and +12 CLL, being this prognosis particularly poor when NOTCH1, 
SF3B1, TP53, BIRC3 and BRAF were also mutated. The presence of these mutations not 
only was an independent risk factor within IGHR-CLLs, but also refined the prognosis of 
low-risk cytogenetic patients (13q-/normal FISH). Hence, our study demonstrates that 
IGHR-CLLs have a distinct mutational profile from the majority of CLLs and highlights 
the relevance of incorporating NGS and the status of  IGH  by FISH analysis to refine the 
risk-stratification CLL model.  




Chronic lymphocytic leukemia (CLL) is a disease that displays extreme clinica l 
heterogeneity, clearly reflecting the marked biological diversity, which has led to the 
identification of a plethora of  prognostic markers1-4. Chromosomal abnormalities are the 
hallmark of the disease and their correlation to the clinical course has contributed to 
patients risk stratification since the 2000s5. In the last years, CLL molecular and cellular 
biology has been enriched by seminal insights that have led to a better understanding of 
CLL pathogenesis2 and, consequently, to the identification of molecular markers whose 
evaluation is well-established in clinical routine, such as the IGHV mutational status or 
TP53 gene abnormalities. The integration of these markers together with the new relevant 
genetic alterations reported in next-generation sequencing (NGS) studies, specifica l ly 
those of NOTCH1, SF3B1 and BIRC3 genes, could be used to refine Döhner hierarchica l 
cytogenetic model2,6-12. 
Although more than 80% of CLL patients carry cytogenetic alterations, chromosome 
14q32 rearrangements/translocations involving the immunoglobulin heavy chain gene 
(IGH) was considered a rare aberration affecting fewer than 4% of CLL patients5,13. 
Nevertheless, with the emergence of new molecular approaches and large-scale genomic 
studies in CLL, a higher incidence of IGH rearrangements has been reported in the recent 
years (5-15%) 14-16. This cytogenetic abnormality contributes to CLL pathogenesis by 
deregulating the IGH-partner genes17,18 and their prognostic significance is still 
controversial. Previous studies have shown that patients carrying 14q32 rearrangements 
(IGHR-CLLs) have an intermediate-adverse outcome19-21, particularly when compared 
with favorable and intermediate-risk cytogenetics22,23. However, some studies have 
reported that patients carrying 14q32 rearrangements with BCL2 have a better clinica l 
course24,25. 
CLL patients with IGH rearrangements are still poorly characterized at the molecular 
level, partly due to the low incidence of cases, the IGHR co-occurrence with other 
cytogenetic alterations, and the difficulty of distinguishing between IGHR-CLLs and 
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forms of non-Hodgkin lymphoma (NHL)26. Furthermore, the IGH probe is not included 
in the classic four-probe CLL FISH panel for the 13q14, 12p11.1-q11, 11q22 and 17p13 
regions used in routine clinical practice26, which is partially responsible for this subgroup 
passing unnoticed. In this study, we characterize the genetic landscape of CLL patients 
with 14q32/IGH translocations for the first time, demonstrating that IGHR-CLLs have a 
distinct mutational profile from other classic cytogenetic groups of CLLs,  dependent on 
whether BCL2 is involved or not in the IGH rearrangement, and as well as the presence 
of certain mutations. Taken together, our results improve our understanding of the 
molecular underpinnings of this cytogenetic CLL subgroup, allowing us to refine the 
prognosis of IGHR-CLL patients. 
METHODS 
Patients 
The study was based on 862 CLL patients, diagnosed according to the Internationa l 
Workshop on CLL (IWCLL) criteria27,28. All of them were screened for IGH translocation 
and positive cases for IGH rearrangement were individually reviewed to rule out the 
possibility that they represented a different lymphoproliferative disorder (see 
Supplementary Methods). Samples and clinical data were collected from 16 Spanish 
institutions.  
Mutational analysis was performed in 233 untreated CLL patients: 46 with 14q32/IGH 
rearrangements and 187 as the control group. Patients in the control group were selected 
according to sample and clinical data availability and absence of treatment and were 
representative of the disease in terms of demographic and clinical characterist ics 
(Supplementary Table S1). Patients risk classification criteria is described in 
Supplementary Methods and a diagram of the patients included in the different outcome 
analyses is shown in Supplementary Fig. S1. 
In the IGHR-CLL group, the median time between diagnosis and IGH rearrangement 
detection was 1 month (range, 0-117 months), and the median follow-up was 57 months 
(range, 1-157 months). Within IGHR-CLLs, 31/46 (67.4%) received treatment after FISH 
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test, with a median TFT of 19 months (range: 7-30). Most of them (93.5%) received 
conventional chemoimmunotherapy and 2 patients were treated with ibrutinib.  
The study was approved by the local ethical committee (Comité Ético de Investigación 
Clínica, Hospital Universitario de Salamanca). Written informed consent was obtained 
from all participants before they entered the study. 
Fluorescence in situ hybridization (FISH)  
Interphase FISH was performed on peripheral blood or bone marrow samples using the 
following commercially probes: ATM, CEP12, D13S319 and TP53 (Vysis, Abbott 
Laboratories, IL, USA). Dual color break-apart FISH probes were performed for 
IGH/BCL2 and IGH/BCL6 translocations. The methods used for FISH analysis have been 
described elsewhere29. Signal screening was carried out in at least 200 cells with well-
delineated fluorescent spots. In all cases, a score of ≥10% was considered positive, based 
on the cut-off value used by our laboratory. 
Next-generation sequencing 
NGS studies were performed in 233 cases and in the same sample as the FISH test. 
Genomic DNA was isolated from peripheral blood or bone marrow by magnetica l ly 
activated cell sorting (MACS) CD19+ B-lymphocytes. B cell purity was greater than 98% 
by flow cytometry, as previously described in our group30. The Agilent SureSelectQXT  
Target Enrichment system for Illumina Multiplexed Sequencing (Agilent Technologies, 
Santa Clara, CA, USA) was used to produce libraries of exonic regions from 54 genes 
CLL-related as well as from BCL2, IGLL5 and NOTCH1 UTR regions (Supplementary 
Methods). Genes included in the custom-designed panel31,32 are involved in CLL 
pathogenesis and the UTR regions were considered due to the previous identification of 
IGLL5, BCL2 and NOTCH1 UTRs somatic mutations in CLL8,33,34. (Supplementary 
Table S2). Paired-end sequencing (151-bp reads) was run on the Illumina NextSeq 
instrument (Illumina, San Diego, CA, USA). 
 
Data analysis 
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Raw data quality control was performed with FastQC (v0.11.8) and Picard tools (v2.2.4) 
to collect sequencing metrics. Demultiplexed files (FASTQ) were aligned to the reference 
genome (GRCh37/hg19 genome), read duplicates were marked with SAMTools (v1.3.1) 
and post-alignment was performed with GATK (v3.5). Coverage for each region was 
assessed using BEDTools (v.2.26.0). A minimum quality score of Q30 was required for 
ensuring high-quality sequencing results. Finally, somatic variant calling, and annotation 
were performed using an in-house pipeline, based on VarScan (v2.4) and ANNOVAR 
(v.2017Jul16), respectively.  
Median coverage of target regions was 600 reads/base, with at least 100X in 97% of them. 
To validate variants detected with VAF <5% using the custom panel, samples were 
conducted to resequencing using different amplicon-based approaches (Illumina Nextera 
XT/454 Roche30) with read depth above 1000X, allowing to report variants down to 2% 
(Supplementary Methods). 
Data was then filtered according to the severity of the consequence, considering variants 
that lead to an amino acid change in the protein sequence (missense, nonsense, frameshift) 
and those in the splice site and UTRs. To discard single nucleotide polymorphisms 
(SNPs), minor allelic frequencies (MAFs) were consulted in several databases (dbSNP, 
1000 genomes, ExAC and our in-house database) and only variants with a MAF of <0.01 
were selected for further analysis. In addition, variants with a VAF between 40-60% or 
greater than 90% were manually reviewed prioritizing variants described in in silico tools 
(Polymorphism Phenotyping v2 (PolyPhen-2), Sorting Intolerant From Tolerant (SIFT) 
and ClinVar) as deleterious, damaging, pathogenic or likely pathogenic. 
Aligned reads were manually reviewed with the Integrative Genomics Viewer (IGV) to 
confirm and interpret variant calls and reduce the risk of false positives. Variants 
described in the Catalogue of Somatic Mutations in Cancer database (COSMIC82 
database) or mutations in driver genes previously described in seminal papers were 
rescued for the analysis (CLL and non-Hodgkin lymphoma)7,8,33,35-37. Manually screening 
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in VarSome and International Cancer Genome Consortium (ICGC) Databases was 
performed for assessing the functional impact of mutations. 
 
Statistical analysis 
Statistical analyses were performed using IBM SPSS v23.0 for Windows (IBM Corp., 
Armonk, NY, USA) and SDM-PSI v6.21 software for the false discovery rate (FDR) 
correction in multiple comparisons. Continuous variables were analyzed with the Mann-
Whitney U test, while the chi-square and Fisher’s exact tests were used to assess 
associations between categorical variables. Overall survival (OS) and time to first therapy 
(TFT) were calculated from the date  FISH test was performed to the date of death, first 
treatment or last follow-up (considering disease-unrelated deaths as competing events). 
Statistically significant variables related to OS and TFT were estimated by the Kaplan-
Meier method, using the log-rank test to compare the curves of each group. Univar iate 
and multivariate analyses of the OS and TFT employed the Cox regression method. 
Results were considered statistically significant for values of P<0.05. FDR was used to 
correct P-values for multiple hypothesis testing when appropriate, by applying the 
Benjamini and Hochberg method38. Adjusted P-values (Q-values) were considered 
significant when Q < 0.1. 
RESULTS 
CLL patients with IGH translocations have a distinct mutational profile with high 
mutation frequencies in NOTCH1, BCL2, FBXW7, ZMYM3 and MGA  
NGS analysis of the 233 CLL patients revealed that 75% of cases had at least one 
mutation in any of the 54 genes included in the targeted-NGS approach, and the median 
frequency of mutations per patient was 2 (range: 0-7). The most frequently mutated genes 
were NOTCH1 (19.3%), IGLL5 (15%), SF3B1 (10.7%), TP53 (10%), ATM (9%), POT1 
(8.5%), RPS15 (6.9%), CHD2 (6%), NFKBIE (5.1%), BIRC3 (5.1%) and XPO1 (4.3%). 
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Regarding the 46 IGHR-CLLs, we identified a total of 109 mutations located in 35 genes. 
The median frequency of mutations per patient was 2 (range: 0-6), and 82% of patients 
(38/46) harbored at least one mutation. Moreover, 61% of patients (28/46) presented more 
than one mutated gene. The most frequently mutated genes in this cohort were NOTCH1 
(30.4%), IGLL5 (17.4%), SF3B1 (13%), POT1 (13%), TP53, BCL2, FBXW7, ZMYM3 
and MGA (8.7% each) followed by BRAF, EGR2 and RPS15 (6.5% each) (Fig. 1A; 
Supplementary Table S3). Other genes such as ATM (4.3%) or CHD2 and MYD88 
(2.2% each) were mutated at low frequencies. 
The comparison between the mutational profiles of IGHRs-CLLs and the control group 
showed higher mutation frequencies in NOTCH1, BCL2, FBXW7, ZMYM3 and MGA 
within IGHR-CLLs, especially those of BCL2 and FBXW7 (Q=0.048, Q=0.06, 
respectively) (Fig. 1A; Supplementary Table S3). 
Furthermore, 61% of IGHR-CLLs (28/46) carried additional FISH alterations (Fig 1B). 
Their mutational profile was analyzed with respect to the presence of IGHR together with 
13q, 11q, 17p deletion or trisomy 12, and only TP53 mutations were significant ly 
associated with 17p or 11q deletion in IGHR-CLLs (Q=0.048). We observed that the 
mutational profile of patients with IGHR as a sole aberration (18/46) was similar to that 
of the entire IGHR-CLL cohort: NOTCH1 (33.3%), IGLL5 (27.8%), SF3B1 (16.7%), 
BCL2, ZMYM3, MGA and FUBP1 (11.1% each) followed by FBXW7 and BRAF (5.6% 
each). All mutation frequencies are shown in Supplementary Table S4. 
Interestingly, we reported a higher incidence of IGLL5, BCL2 and HIST1H1E mutations 
in this subgroup compared to the described in previous large-scale CLL studies7,8 (Fig. 
1B). IGHR-CLL patients showed IGLL5 mutations targeting the signal peptide domain 
(4/10) and the 5’UTR region (3/10), BCL2 mutations affecting the 5’UTR region (2/6) 
and the exon 2 (4/6), and HIST1H1E mutations located in the exon 1 (Fig 2). According 
to the ICGC Database, most of the coding mutations in IGLL5 (6/7), BCL2 (3/4) and 
HIST1H1E (1/2) identified in our study, had functional impact in the gene function (Table  
1). In addition, six out of 17 mutations detected in the aforementioned three genes were 
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previously described in non-Hodgkin lymphomas (as reported in the COSMIC and ICGC 
database and whole-exome and whole-genome data from NHL patients35-37,39,40). 
Moreover, five of the mutations reported in IGLL5 and BCL2 were located in the 5’UTR 
of the gene. Specifically, the novel BCL2 recurrent mutation identified in the 5’UTR 
region (genomic position chr18:60985900) was exclusively found in IGHR-CLLs when 
compared with the control group (P=0.048) (Supplementary Fig. S2). 
Detailed lists of the mutations detected in the IGHR-CLLs and the control group are 
shown in Supplementary Tables S5, S6 and S7. 
CLL patients with IGH/BCL2 exhibit a lower mutation frequency and a different 
mutational profile than patients with other IGH translocations 
 
We next sought to assess whether the mutational landscape changes depend on the IGH 
translocation partner, e.g. BCL2 and BCL6. In our study, 13/46 patients (28%) carried 
IGH/BCL2 translocation (Figure 1B) and 2/46 (4.3%) harbored an IGH/BCL6 
rearrangement (ID 8 and 20). Due to the small number of BCL6 rearrangements, we 
performed further analysis comparing IGH/BCL2 vs. the rest of IGHR cases.  
In the IGHR patients, fewer CLLs with IGH/BCL2 translocation had mutations in at least 
one gene compared with the subgroup with other IGH translocations (7/13, 54% vs. 31/33, 
94%; P=0.001). The median mutation frequency per patient was significantly lower in 
the group with IGH/BCL2 compared with that without it (1 vs. 2, P=0.030).  
The most frequently mutated genes in the IGH/BCL2 group were BCL2 (23%), IGLL5 
(23%), HIST1H1E (15%) and NOTCH1 (15%), whereas for all other IGHR-CLLs, the 
most frequently mutated genes were NOTCH1 (36%), SF3B1 (18%), POT1 (18%), TP53 
(12%), and FBXW7 (12%) (Supplementary Fig. S3A). It is worth mentioning that 
neither TP53 nor SF3B1 mutations, widely associated with poor prognosis, were detected 
in CLL patients with an IGH/BCL2 translocation, reflecting a different mutational profile 
from all other IGHR-CLLs. The mutational analysis of 9 IGH/BCL2 cases previously 
reported in a WES/WGS study of CLL8 also showed the presence of mutations in BCL2, 
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and NOTCH1, and the absence of poor-prognosis genes such as TP53 or SF3B1 
(Supplementary Fig. S3B). They have been previously reported in WES of However, no 
statistically significant associations were detected in our analysis, probably due to the 
small number of cases (Supplementary Table S8). 
In IGH/BCL2 cases that also harbored BCL2 mutations, we observed that 60-87% of the 
cells carried the rearrangement, while BCL2 mutations VAFs range from 11% to 40%, 
suggesting that somatic mutations occurred later in time than the rearrangement (Table  
1). 
Patients carrying IGH translocations exhibit an intermediate-adverse outcome 
 
We also analyzed the clinical and biological characteristics of IGHR-CLLs within the 
entire cohort (n=862) (Table 2). Patients carrying this cytogenetic alteration showed a 
higher incidence of poor prognosis markers such as Binet stage B or C (Q=0.039), high 
β2-microglobulin (Q=0.0007) and lactate dehydrogenase levels (Q=0.054), unmutated 
IGHV) (Q=0.054) and need for treatment (Q=0.007). In addition, two IGHR-CLLs 
developed Richter syndrome during follow-up (patient IDs: 18 and 35). Regarding the 
presence of additional cytogenetic alterations, 34.8% of IGHR-CLL patients (16/46) 
carried trisomy 12, showing significant co-occurrence of the two events (trisomy 12 and 
IGHR) (Q=0.0007). By contrast, the presence of the 13q deletion in IGHR-CLLs was 
significantly less frequent than in CLLs without IGH rearrangements (Q=0.0014) (Table  
2). 
Within IGHR-CLLs, 31/46 (67.4%) received treatment after FISH test, with a median 
TFT of 19 months (95% CI, 7-30 months). Patients with an IGH translocation showed 
shorter TFT than the 13q- and normal FISH subgroups (median: 19 vs. 120 and 184 
months; p<0.0001, p<0.0001), and longer TFT than the 11q- and 17p- subgroups (19 vs. 
5, 6 months; p=0.042, p=0.31). The median TFT of the +12 subgroup was slightly higher 
than that of IGHR-CLLs (28 vs. 19 months; p=0.37). In terms of OS, we observed similar 
trends (Supplementary Fig. S4A). Differences in outcome among the cytogenetic 
subgroups were consistent with the prevalence of unfavorable clinical and biologica l 
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features in IGHR-CLLs, suggesting that this subgroup exhibits an intermediate-adverse 
prognosis. In addition, the clinical comparison between IGHR-CLLs and control CLLs 
selected for the mutational analysis (n=233) showed quite similar results to the presented 
in this section, also demonstrating that control group was representative of the entire 
cohort (Supplementary Table S1) (Supplementary Fig. S4B). 
In our entire cohort (n=862), 31% of patients showed no alterations using 13q14/ 
D13S319, 12p11.1-q11/CEP12, 11q22/ATM, 17p13/P53 probes. However, it is worth 
mentioning that 6.7% of patients who would be classified as normal FISH in our cohort 
using the four-probe CLL FISH panel customarily used in routine clinical practice, 
actually carried an IGH rearrangement. The presence of this cytogenetic alteration had a 
negative effect on the time to first treatment within this group of patients: CLL patients 
with IGHR as the sole FISH abnormality had a significantly shorter TFT than those 
without any FISH aberration (23 vs. 120 month, P =0.01) (Fig. 3A).  
The presence of the IGH/BCL2 translocation was associated with mutated IGHV 
(P=0.001), and patients with this alteration showed a longer TFT than those with another 
IGHR (56 vs. 4 months, P=0.05). By contrast, the presence of IGH/BCL2 rearrangement 
was not associated to any additional cytogenetic alteration (13q-, Q=0.822; +12, 
Q=0.822; 11q-/17p-, Q=0.822) and there was no significant difference in terms of OS 
between patients with IGH/BCL2 and patients with other IGH rearrangements (P=0.433) 
(Supplementary Fig. S5).  
Genetic mutations refine the prognosis of IGHR and low-risk cytogenetic CLL 
patients 
IGHR-CLL untreated patients with at least one mutated gene showed a shorter TFT than 
IGHR-CLLs without gene mutations  (10 months vs. median TFT not reached, P=0.026) 
(Fig. 3B). These differences were more significant among recurrent gene mutations 
previously associated with worse prognosis (NOTCH1, SF3B1, TP53, BIRC3 and BRAF) 
(2 vs. 88 months, P <0.0001) (Fig. 3C). Specifically, TFT was shorter in IGHR patients 
with TP53 mutations (0 vs. 23 months, P <0.0001) as well as with BRAF mutations (2 vs. 
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23 months, P =0.042) (Supplementary Fig. S6). In contrast, the presence of IGLL5 or 
BCL2 mutations showed a better impact in terms of TFT, as IGHR-CLL patients with 
mutated IGLL5 or BCL2 showed a longer TFT than those without mutations in any of 
these genes (median TFT not reached vs. 9 months, P=0.001) (Fig. 3D). 
In the univariate analysis, other variables associated with a shorter TFT were Binet’s stage 
B/C (P=0.001), splenomegaly (P=0.025), unmutated IGHV status (P=0.013), TP53 
disruption/mutation (P=0.003) and the absence of IGLL5/BCL2 mutations (P=0.008). 
Only the presence of mutations in NOTCH1, SF3B1, TP53, BIRC3 and BRAF was 
significantly related to a shorter TFT within IGHR-CLL patients in the multivar iate 
analysis (HR=0.255, 95% CI=0.07-0.9, P=0.030) (Table 3). 
Since the presence of mutations in these five genes  has a prognostic impact within IGHR-
CLL patients as well as in the control group (median TFT not reached vs. 12 months, 
P<0.0001) (Supplementary Fig. S7), we propose an integrated mutational and 
cytogenetic model to account for our observations in the studied cohort (187 control and 
46 IGHR-CLLs). Low-risk patients in our control series (13q-/normal FISH, n=134) 
segregated into two groups according to the presence of mutations in NOTCH1, SF3B1, 
TP53, BIRC3 and BRAF (median TFT not reached vs. 24 months, P<0.0001) (Fig. 3E). 
These mutations also contributed to a worse outcome in intermediate-risk patients (IGHR 
/+12, n=72) (56 vs. 2 months, P<0.0001). However, the small number of cases with these 
mutations was insufficient to demonstrate a statistically significant difference in clinica l 
impact in the high-risk cytogenetics subgroup (11q-/17p-, n=27) (4 vs. 0 months, 
P=0.580). The median TFT of those intermediate-risk patients with mutations was similar 
to that of patients with high-risk cytogenetic alterations (2 vs. 5 months; P=0.548), and 
the TFT of low-risk patients with mutations was not significantly different from that of 
intermediate-risk patients without mutations in any of the five genes (24 vs. 56, P=0.210).  
Therefore, by including NOTCH1, SF3B1, TP53, BIRC3 and BRAF mutations in the 
cytogenetic model, approximately 27.6% (37/134) of low-risk patients were reclassified 
into an intermediate-risk subgroup, and 51% (35/72) of intermediate-risk patients were 
reclassified into a high-risk subgroup (Fig. 3E). 




The identification of novel recurrent mutations in CLL has provided a more 
comprehensive perspective on the genomic landscape and the biological mechanisms 
underlying the clinical heterogeneity of the disease2-4,7,8. Previous studies have shown that 
CLLs carrying IGH rearrangement could have a worse outcome than low-risk cytogenetic 
CLL patients22,23. However, their clinical course and molecular characteristics are not 
well defined19-24. Here, we adopted a targeted NGS approach to assess for the first time 
the mutational profile of 46 IGHR-CLL patients. 
Overall, the mutational analysis revealed that IGHR-CLL patients had a high incidence 
of mutations, not only in well-known CLL drivers such as NOTCH1, SF3B1, POT1, TP53 
and FBXW7 —previously described in unselected large CLL cohorts—, but also in less 
commonly mutated genes such as BCL2, FBXW7, ZMYM3 and MGA7,8,33, being BCL2 
and FBXW7 significantly associated with the IGH translocation (Fig 1A). Although we 
observed the co-occurrence between IGHR and trisomy 12 previously described, we 
demonstrated that IGHR-CLLs mutational profile did not depend on the presence of 
additional cytogenetic aberrations: CLLs with only IGHR also exhibited a high mutation 
frequency in genes well-known associated with trisomy 12 such as NOTCH18, as well as 
in the majority of recurrently mutated genes in the entire IGHR-CLL cohort (Fig. 1B). 
Strikingly, several IGHR-CLLs showed mutations in IGLL5, BCL2 and HIST1H1E, 
mainly those with IGH/BCL2 translocations (Supplementary Fig. S3A). Although these 
gene mutations have been detected at low frequencies in other CLL cohorts7,8, they have 
been extensively reported in other hematological malignances such as diffuse large B-cell 
lymphoma (DLBCL) and follicular lymphoma (FL)35-37,39-44 (Table 1). Considering that 
our series of IGHR-CLL patients is well characterized at the immunophenotypic and 
clinical levels, the presence of mutations previously described in lymphomas suggests 
that patients with IGH translocation are a cytogenetic subgroup with a mutational profile 
distinct from the other CLLs and, probably, with different genetic mechanisms underlying 
their disease pathogenesis. Here, we demonstrated that IGHR-CLLs had an intermed iate 
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genetic landscape between those of CLL and non-Hodgkin lymphoma, and we suggest 
that the mutational analysis of patients with IGH translocations such as IGH/BCL2 could 
help distinguish between CLL and NHL cases.  
In this work, we have reported mutations in coding and non-coding regions of BCL2 and 
IGLL5 and, specifically, we identified a novel recurrent 5’UTR mutation in BCL2. 
Although this mutation has not been previously described, proximal mutations have been 
detected in other CLL and NHL studies8,34,44. Moreover, the vast majority of BCL2 
mutations reported in Puente et al. were detected in cases harboring IGH/BCL2 
translocations8, which is consistent with our results (Supplementary Fig. S3). Regarding 
IGLL5, a previous study identified 5’UTR and coding mutations in low-risk IGHV-
mutated CLLs as well as in the presence of rearrangements33. These statements are 
consistent with our results, as most of patients harboring mutations in both genes 
exhibited mutated IGHV and were associated with longer time to first treatment (Fig. 3D). 
In addition, data compiled in the ICGC repository suggested a functional impact of the 
BCL2 and IGLL5 coding mutations in the gene function. However, the functional impact 
of UTR somatic mutations has not been well-established yet. Puente et al. demonstrated 
the negative impact of the 3’UTR mutation in NOTCH18 and recent findings from the 
Pan-Cancer Analysis of WholeGenomes (PCAWG) Consortium identified novel driver 
candidates, including mutations in UTR regions, with a potential role in CLL 
pathogenesis45. Nevertheless,  further investigation is needed in order to determine the 
importance of BCL2 and IGLL5 non-coding mutations in CLL. 
The clinical impact of IGH translocations is currently under discussion19-25. The median 
TFT was shorter in IGHR-CLLs than that of patients with low-risk cytogenetic 
alterations, but similar to that of patients with trisomy 12 (Supplementary Fig. S4A), 
indicating that IGH translocations could be associated with an intermediate-adverse 
outcome. Indeed, 6,7% of CLL patients who would be considered ‘normal FISH’ using 
the customary four-probe CLL FISH panel in our study, carried the IGH translocation 
and also had a worse prognosis than CLLs lacking IGHR (Fig. 3A), thus highlighting the 
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value of including the IGH probe in the CLL FISH panel to improve patient outcome 
prediction25.  
Previous studies have shown that patients with a IGH/BCL2 translocation had a favorable 
clinical course, similar to that of patients with low-risk chromosomal alterations, whereas 
patients with other IGH rearrangements had a similar prognosis to the high-r isk 
subgroups24,25. In our study, patients with IGH/BCL2 not only were associated with 
IGHV-M and longer TFT (Supplementary Fig. S5A), but also exhibited lower mutation 
rate compared with other IGH translocations that may contribute to understand why these 
entities have a better prognosis than the rest of IGHR. Regarding the mutational profile 
of IGH/BCL2 translocations, a previous large-scale CLL study showed mutations in 
BCL2, IGLL5 and NOTCH1 within 9 IGH/BCL2 cases, which strongly supports our 
findings (Supplementary Fig. S3B). On the other hand, IGHR-CLLs without IGH/BCL2 
rearrangement presented higher mutation frequencies in genes related to bad prognosis, 
such as NOTCH1, SF3B1, TP53, BRAF and RPS15 (Fig. 1B; Supplementary Fig. S3A). 
The high frequency of these mutations may reflect a genomic instability in IGHR-CLLs 
without IGH/BCL2, which could be also influenced by the role of the translocated partner 
in the rearrangement. Furthermore, two IGHR-CLLs developed Richter transformation to 
DLBCL. One of them harbored IGH/BCL2 rearrangement together with trisomy 12 and 
NOTCH1, and the other patient had an IGHR with unknown partner, NOTCH1 and TP53 
mutations. These observations are in line with previous findings regarding the molecular 
pathways frequently altered at transformation46,47. Altogether, these molecular 
characteristics could be the underlying mechanisms of the IGHR-CLLs poorer outcome25. 
In our cohort, patients harboring NOTCH1, SF3B1, TP53, BIRC3 or BRAF mutations 
experienced an adverse clinical course (Fig. 3C), which is consistent with previous 
studies6-8,11,48. Within IGHR-CLLs, the presence of these mutations contributed to shorter 
TFT being identified as an independent adverse prognostic factor (Table 3). Specifica lly, 
IGHR-CLL patients harboring BRAF mutations exhibited an adverse outcome 
(Supplementary Fig. S6A), which corroborates previous results showing that patients 
carrying these mutations display an aggressive disease 49,50.  
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Therefore, the present study proposes an integrated mutational and cytogenetic model for 
CLL prediction that includes IGHR and BRAF mutational status as novel components 
with respect to previous prognostic models9,10. The presence of mutations in any of the 
aforementioned five genes caused a significant shift to a more aggressive outcome in low 
(13q-/normal FISH) and intermediate-risk (+12/IGHR) CLLs, refining their prognosis 
and providing information that could help in therapeutic decisions. Interestingly, low-risk 
patients with mutations in NOTCH1, SF3B1, TP53, BIRC3 or BRAF still had a 
significantly better outcome than did intermediate-risk patients with any of those 
mutations (Fig. 3E). These results may indicate that the co-occurrence of cytogenetic 
abnormalities and gene mutations could have different clinical impacts, depending on the 
type of the genetic alterations involved. 
In conclusion, our study revealed significant differences in the mutational profile and the 
frequencies of CLL-mutated genes in patients with IGH rearrangements. The distribut ion 
of genetic mutations differed within the IGHR-CLL subgroup: patients with IGH/BCL2 
translocation had higher frequencies of BCL2 and IGLL5 mutations than those without 
the translocation. Conversely, patients with other IGHR showed higher mutation 
frequencies of genes related to bad prognosis (NOTCH1, SF3B1, TP53, BIRC3 and 
BRAF) than did those with the IGH/BCL2. Notably, the presence of those somatic 
mutations enables us to refine not only the prognosis of IGHR-CLLs but also the outcome 
of low-risk cytogenetic patients. Thus, this mutational analysis improves our 
understanding of the molecular heterogeneity of CLL patients and could help improve 
prognostic stratification of CLLs. 
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Figure 1. Mutational profile of CLL patients with IGH rearrangements. A) 
Mutational frequencies and associations in the CLL cohort according to the presence of 
IGH rearrangements. Significant p/q-values are annotated with asterisks (N=233). B) 
Each column represents a patient; each row corresponds to a genomic alteration. Patients 
are clustered according to the IGHR (IGH/BCL2 translocation is indicated in light blue; 
other IGH translocations are shown in dark blue). Missense, frameshift, nonsense, 
splicing and UTR mutations are reported in red, green, yellow, pink and brown, 
respectively.  The presence of a cytogenetic alteration is shown in gray and the IGHV 
unmutated status is represented in purple (N=46). 
Figure 2. Schematic representation of BCL2, IGLL5 and HIST1H1E mutations . 
Positions of coding mutations are indicated according to the aminoacid change at the 
protein level; positions of UTR mutations are indicated according to the nucleotide 
change in the DNA sequence (GRCh37/hg19 genome); with respect to the UTR regions, 
only BCL2 and IGLL5 5’UTR regions were covered in the sequencing analysis (see 
Supplementary Table S2). Number of cases are denoted by circles in each mutation line 
and the color of the circles indicates the mutation subtype (missense, frameshift and 
nonsense). Mutations identified in the COSMIC database in non-Hodgkin lymphomas 
(NHL) are represented with red lines; mutations reported in the COSMIC database in 
CLL are indicated with blue lines; all other mutations are shown in black. Abbreviat ion: 
Aa, aminoacid. 
Figure 3. Clinical impact of IGHR and genetic mutations in CLL patients. A) 
Kaplan-Meier analysis of TFT according to the presence of IGH translocation in CLLs 
with normal FISH (N=268). Kaplan-Meier analysis of TFT in IGHR-CLL patients with 
B) any mutation, C) NOTCH1, SF3B1, TP53, BIRC3 or BRAF mutations and D) 
IGLL5/BCL2 mutations (N=46). E) Kaplan-meier analysis of TFT in the three risk 
stratifications subgroups according to the presence of mutations in  NOTCH1, SF3B1, 
BIRC3, TP53 and BRAF genes. In low-risk patients, the presence of mutations in some of 
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these five genes is significantly associated with shorter TFT (median not reached vs. 24 
months, P<0.0001) as well as in the intermediate-risk subgroup (56 vs. 2 months, 
P<0.0001). 
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(% of cells) 
Gene DNA
a/cDNA change: 












10 NO BCL2 C60985900G 12.74 5' UTR - - - YES -
41 YES (85) BCL2 C60985900A 33.87 5' UTR - - - YES -
41 YES (85) BCL2 c.G405T:p.E135D 30.15 exonic - - T/P YES UNKNOWN
42 YES (60) BCL2 c.G140A:p.G47D 11.39 exonic COSM220809 DLBCL35 T/P YES YES
35 YES (87) BCL2 c.G589A:p.G197S 40.1* exonic COSM5947452 DLBCL/FL36 -/B YES YES
35 YES (87) BCL2 c.C175T:p.P59S 37.82* exonic COSM4170930 DLBCL/FL36 T/B YES YES
28 NO IGLL5 c.G26C:p.G9A 51.09 exonic COSM5713869 DLBCL T/B YES -
15 NO IGLL5 c.G312T:p.K104N 9.42 exonic - - D/P YES YES
32 NO IGLL5 c.G72A:p.W24X 42.86 exonic - - - - YES
16 NO IGLL5 C23230223- 26.12 5' UTR - CLL33 - - -
16 NO IGLL5 G23230229C 26.51 5' UTR - - - YES -
41 YES (85) IGLL5 c.G88A:p.G30S 33.93 exonic - - D/P YES YES
35 YES (87) IGLL5 c.T167G:p.V56G 19.88 exonic - CLL8 T/B YES YES
35 YES (87) IGLL5 c.C182T:p.S61F 19.88 exonic COSM3357314 CLL8/DLBCL T/B YES YES
35 YES (87) IGLL5 A23230172C 17.58 5' UTR - CLL8 - - -
43 YES (41) IGLL5 c.G94A:p.A32T 43.48 exonic COSM5949859 CLL D/B YES YES
34 YES (77) HIST1H1E c.G515C:p.S172T 42.33 exonic - - D/D - -
37 YES (98) HIST1H1E c.C500T:p.A167V 41.74 exonic COSM1292261 FL39/CLL7 T/B YES YES
*Confirmed as somatic in the matched CD19- cell fraction.
aPositions of UTR mutations are indicated according to the nucleotide change in the DNA sequence (GRCh37/hg19 genome)(reference transcripts: see Suppl. Table S5).
bHaematopoietic and lymphoid tissue
Abbreviations: AA=aminoacid; VAF=variant allele frequency; DLBCL=diffuse large B cell lymphoma; FL=follicular lymphoma; CLL=chronic lymphocytic leukemia; 
T=Tolerable; B=Benign; D=Damaging; P=Pathogenic. 
UNKNOWN: reported in ICGC database with unknown functional impact in the gene. “-“ indicates the variant has not been previously reported in the databases or seminal 
papers.














Median age at diagnosis, years (range) 69 (43-89) 66 (25-97) 0.112b 0.542
Gender Male, % 63 63.8 0.698c 0.814
Median time from diagnosis to FISH, months (range) 1 (0-117) 1 (0-253) 0.568b 0.808
Binet B or C, % 38.6 22.2 0.014c 0.039
Median WBCa count, ·109/L (range) 17.6 (2.3-196) 17.8 (2.4-964) 0.721b 0.841
Median lymphocytes count, ·109/L (range) 11.6 (0.6-186) 12.2 (0.8-960) 0.874b 0.874
Median platelet count, ·109/L (range) 172 (55-295) 187 (2-587) 0.456b 0.808
Median hemoglobin level, g/dL (range) 14.1 (6.6-16.5) 14.2 (4.4-18.9) 0.577b 0.808
High β2-microglobulin level, % 67.4 36.3 <0.0001c 0.0007
High lactate dehydrogenase level, % 27.3 15.7 0.027c 0.054
Hepatomegaly, % 7.1 6.9 0.824c 0.852
Splenomegaly, % 15.9 16.8 0.852c 0.852
B Symptoms, % 11.1 7.9 0.595c 0.757
Richter transformation 4.3 1.7 0.148c 0.259
IGHV-Unmutated, % 60.6 44.9 0.025c 0.054
13q deletion, % 26.1 43.1 0.0003c 0.0014
trisomy 12, % 34.8 14.5 <0.0001c 0.0007
11q deletion, % 4.3 10.9 0.426c 0.596
17p deletion, % 6.5 4.3 0.334c 0.520
Need for treatment, % 67.4 44.0 0.002c 0.007
Median follow-up, months (range) 57 (1-157) 133 (106-159) 0.155b 0.543
a WBC: white blood cells
bMann Whitney U test
cχ2 test










Table 3. Univariate and multivariate analysis for Time to First Treatment (TFT) in IGHR-CLL patients (N=46).
 Univariate Multivariate
95% CI 95% CI
 HR Lower Upper     P HR Lower Upper      P
Male Gender 0.675 0.33 1.37 0.276
Binet B/C 0.257 0.12 0.56 0.001 0.558 0.22 1.43 0.221
CD38 positivity 0.810 0.36 1.82 0.614
IGHV-unmutated 0.325 0.13 0.79 0.013 0.566 0.20 1.64 0.29
LDH high 0.726 0.32 1.66 0.448
β2M high 0.558 0.25 1.27 0.163
Hepatomegaly 0.340 0.10 1.16 0.085
Splenomegaly 0.368 0.15 0.88 0.025 0.403 0.14 1.19 0.099
B symptoms 0.483 0.18 1.27 0.141
11q deletion 0.421 0.09 1.82 0.246
IGH/BCL2 translocation absence 0.443 0.18 1.09 0.076
IGLL5/BCL2 mutations absence 0.139 0.03 0.60 0.008 0.821 0.14 4.76 0.828
TP53 disruption/mutation 0.143 0.04 0.51 0.003 0.304 0.07 1.28 0.105
BRAF mutations 0.325 0.09 1.13 0.076
NOTCH1/SF3B1/TP53/BIRC3/BRAF mutations 0.204 0.08 0.47 0.0002 0.255 0.07 0.88 0.030
Presence of mutation 0.238 0.05 10.0 0.051     
β2M, β2-microglobulin level; LDH, lactate dehydrogenase level.











0 5 10 15
Number of samples affected
Missense Frameshift Nonsense Splicing UTR mutation
IGH/BCL2
Unmutated Mutated


































































































IG H R -C L L  (N = 4 6 )
C o n tro l C L L  (N = 1 8 7 )
*
***** **



















































































































































































































































































































































Exons & UTR regions
aa position
Domains (219 aa)
Exons & UTR regions
aa position
Domains (214 aa)








60985900: C > G
60985900: C > A
23230172: A > C
23230223: C > -





































































































































































SP J Ig-like-C1-type1 1 0 2 0
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Normal FISH without IGHR
median 120 months
N=250
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Low risk wt vs low risk mut p<0.0001
Interm. risk wt vs interm. risk mut p<0.0001
Low risk mut vs interm. risk wt p=0.210
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